HSBC Upgrades UBTech to Buy: Humanoid Robot Mass Production Is Faster Than Expected

Overview

This report is part of HSBC’s humanoid robot research series, focusing on the differences in commercialization paths for UBTech and UniTree. HSBC views sector mass production as already picking up, with government-supported data-collection use cases as one of the near-term main demand sources. UBTech focuses on industrial full-size embodied humanoid robots used in factories and data-collection sites, while UniTree leans toward mid-size consumer humanoid robots used mainly for exhibitions, research, universities, and channel customers.

Core views

HSBC’s core view is that UBTech’s shipment and revenue growth are faster than previously expected, and that industrial full-size embodied solutions have stronger practicality and higher technical barriers in factory settings. A higher share of humanoid robot revenue is expected to improve 2026 gross margin and potentially deliver operating leverage. Although UBTech is still loss-making, has weaker cash conversion, and faces additional dilution risk, faster mass production, new model launches, large orders, and sector repricing from UniTree’s A-share IPO may act as catalysts.

Analysis framework

The report assesses UBTech through cross-company comparison, shipment forecast revisions, revenue and gross margin forecast revisions, cash quality analysis, and relative valuation. Comparison dimensions include product positioning, ASP, customer mix, R&D expense ratio, days receivables outstanding, commercialization speed, mass-production capability, and profitability inflection point. For valuation, HSBC uses Tesla’s forward P/S as a reference and applies a one-standard-deviation discount for UBTech’s dilution risk, ultimately using 9.7x 2027e P/S.

Methodology notes

• Valuation methodTarget P/S multiple method

  Derives the target price using 2027e sales as the base and a 9.7x target P/S multiple.

  HSBC views Tesla as comparable because Optimus and UBTech’s Walker are both full-size industrial humanoid robots, making it a valuation reference; however, it applies a discount equivalent to one standard deviation below Tesla’s trailing one-year forward P/S average to reflect UBTech’s potential dilution risk.

• Industry peer comparisonProduct, ASP, customer structure, and cash quality comparison

  Compares the differences in business model and financial quality between UBTech and UniTree.

  UBTech is more industrial-oriented with higher ASP and a customer base dominated by government, automotive, and manufacturing; UniTree is more mid-size and consumer-oriented with lower ASP, and its customers are mainly research institutions, universities, and dealers with higher prepayment ratios and shorter DSO.

• Earnings forecastShipment, revenue mix, and gross margin drivers model

  Revises earnings forecasts through humanoid robot shipment volume, ASP, revenue mix, and gross margin changes.

  HSBC raised UBTech’s 2026 humanoid robot shipment forecast to 4,000 units, expecting full-size embodied humanoid robot revenue to rise 215% yoy to RMB2.6bn in 2026, representing 69% of total revenue and supporting a higher consolidated gross margin.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• UBTech (9880 HK)

  Core covered company and rating adjustment target

  Strengths

  Focuses on industrial full-size embodied humanoid robots with higher technological barriers; collaboration with automotive and manufacturing customers helps it gain real-world data; annualized humanoid robot capacity has already exceeded 6,000 units and is ramping toward 10,000 within the year.

  Weaknesses

  Still in a loss-making phase, has long receivables collection periods, and is expected to remain a net cash outflow from 2025 to 2027; six rights issues since IPO.

  Comparison

  Compared with UniTree, UBTech has a higher ASP and stronger practical relevance in industrial scenes, but weaker commercialization speed and cash conversion quality.

  Risks

  Potential weakening of government data-collection site orders, customer payment delays, dilution pressure, intensifying competition, and failure of costs to decline as expected.

• UniTree

  Key peer and one sector repricing catalyst

  Strengths

  Lower ASP mid-size consumer product line with faster commercialization; shipped 5.5k units in 2025 and reached net profit breakeven.

  Weaknesses

  More consumer and event/exhibition oriented, with lower practicality and weaker technological barriers in industrial factory scenes than UBTech’s full-size solution.

  Comparison

  UniTree’s 2025 ASP is about RMB168k, below UBTech’s RMB760k; R&D expense ratio is about 8%, below UBTech’s 25%.

  Risks

  If the A-share IPO or sector repricing is weaker than expected, the sector valuation catalyst may fade.

• Tesla (TSLA US)

  Valuation peer reference

  Strengths

  Optimus and UBTech Walker are both full-size industrial humanoid robots, giving the pair valuation relevance.

  Weaknesses

  Tesla’s business mix is not fully consistent with UBTech, so direct comparability is limited.

  Comparison

  HSBC references Tesla’s trailing one-year forward P/S average and applies a one-standard-deviation discount to UBSTech, resulting in 9.7x 2027e P/S.

  Risks

  If Tesla’s or the broader humanoid robot sector valuation compresses, UBTech’s target valuation multiple could be pressured.

Key data

• Global humanoid robot shipments2025: 18k units, 2024: 2.3k unitsIndicates that sector mass production has started to accelerate.
• UBTech 2025 full-size humanoid robot shipmentsabout 1,076-1,079 unitsSignificantly above 5 units in 2024 and above HSBC’s prior estimate of 750 units.
• UBTech 2026 shipment forecast4,000 unitsRaised from 2,600 units, mainly supported by government data-collection site orders.
• 2026 global humanoid robot shipment base forecast31k unitsBase-case forecast for the overall humanoid robot market.
• UBTech humanoid robot ASPRMB760kHigher than UniTree’s RMB168k, reflecting the industrial full-size positioning.
• UniTree 2025 shipments5.5k unitsLower ASP and lower R&D expense ratio support faster commercialization.
• R&D expense ratio comparisonUniTree 8% vs UBTech 25%UniTree on a 9M25 annualized basis, UBTech on a 2025 basis.
• Days sales outstandingUBTech 268 days vs UniTree 19 daysReflects differences in customer structure and cash conversion quality.
• UBTech 2026 full-size embodied humanoid robot revenue forecastRMB2.6bn, up 215% YoYExpected to account for 69% of 2026 revenue.
• UBTech 2026 consolidated gross margin forecast43.6%, up 5.9pptImproved by a higher share of high-margin humanoid robot revenue.
• Earnings inflectionExpected 2027e net profit breakevenImproving operating leverage is a key assumption.
• Target price and ratingBuy, HKD126.00, 16% upsideTarget price raised from HKD124.00.

Impact & implications

The investment implication of the report is constructive: if UBTech delivers on the 4,000-unit 2026 shipment target, maintains industrial customer orders, and improves gross margin, the market may recognize a shorter path to the earnings break-even. At the sector level, UniTree’s A-share IPO, new product launches, and large orders could re-rate the humanoid robot segment. Investors should still monitor UBTech’s cash flow, receivables, potential dilution, and competitive intensity, which could pressure valuation and profitability.

Risks

• Government data-collection site orders may weaken, leading to slower near-term robot shipments.
• Commercialization may progress slower than expected, affecting longer-term shipment and revenue growth.
• Pilot partners may fail to convert into actual orders, weighing on humanoid robot revenue growth.
• Supplier cost-down may be slower than expected, resulting in lower humanoid robot gross margins than forecast.
• More players entering the humanoid robot industry and beginning deliveries could force UBTech into direct competition for incremental orders and compress margins.
• Competition in traditional businesses such as consumer, education, logistics, and industry custom robots may pressure ASP.
• R&D or selling expenses higher than expected could delay net profit breakeven.
• Weaker-than-expected operating leverage improvement could further delay the profitability inflection.
• Additional rights issues could pressure the share price.
• If receivables recovery does not improve or government customer payment delays persist, additional impairment losses may occur.

What to watch

• Progress of new product launches in 2Q.
• Success in securing large orders from government and commercial customers.
• The impact of UniTree’s A-share IPO on humanoid robot sector valuation.
• Execution against UBTech’s 4,000-unit shipment target in 2026.
• Progress in ramping annualized capacity from above 6,000 units toward 10,000 units.
• Whether humanoid robot ASP declines in line with BOM cost reductions.
• Whether consolidated gross margin can rise to 43.6% as forecast.
• Whether days sales outstanding and cash flow improve.
• Whether there is another rights issue.
• Industrial progress in dexterous hands, VLA models, and embodied intelligence technology roadmaps.